Kronik migrene dönüşüm üzerine etkili risk faktörlerinin araştırılması

Amaç: Kronik migren (KM), toplumda sık rastlanan, ciddi sosyoekonomik ve kişisel engelliliğe yol açabilen fakat halen tanısal zorlukların yaşandığı bir migren komplikasyonudur. Bu çalışmada amacımız, üçüncü basamak bir başağrısı polikliniğine başvurmuş ve KM tanısı ile takip edilmekte olan hastalarda, kronik migrene dönüşümde etkili olabilecek faktörlerin belirlenmesi ve bu faktörlerin hastalık prognozuna olan etkilerini araştırmaktır. Gereç ve Yöntem: Baş Ağrısı Polikliniğimize, Şubat 2015–Aralık 2017 tarihleri arasında baş ağrısı yakınması ile başvuran hastalar arasından 115 KM ve 377 epizodik migren (EM) hastası çalışmaya dahil edilmiştir. Hastalık başlangıç yaşı, baş ağrısının süresi ve sıklığı, aura varlığı ve tipi, baş ağrısının klinik özellikleri ve lokalizasyonu, ağrının şiddeti, tetikleyici faktörler, aile öyküsü varlığı, VAS ve ASC skorları, allodini varlığı, MIDAS skorları kaydedilmiş ve iki grup istatistiksel olarak karşılaştırılmıştır. KM e dönüşümde bağımsız risk faktörlerinin belirlenebilmesi amacıyla lojistik regresyon yöntemi kullanılmıştır. Bulgular: 492 hastanın (408 kadın, 84 erkek) yaş ortalaması 36,03±12,67 yıl, hastalık süresi 10,78±10,36 yıl, atak sıklığı 10,35±9,06 atak/ay, atak süresi 30,10±23,54 saat idi. KM tanısı olan 115 hasta (104 kadın, 11 erkek) bulunmaktaydı. Kadın cinsiyet (p=0,015), atak sıklığı (p

Investigation of the risk factors for the transition of episodic migraines to chronic migraines

Objectives: Chronic migraine (CM) is a frequent complication of migraines that has a serious impact on personal and social life and is still underdiagnosed. The aim of this study was to determine risk factors for the progression to CM and to investigate the relationship of these factors to the disease prognosis. Methods: In all, 115 CM and 377 episodic migraine patients from between February 2015 and December 2017 were enrolled. The age of disease onset, headache duration and frequency, presence of aura and type of aura, clinical properties and location of headache, pain severity, trigger factors, presence of family history, visual analogue scale (VAS) and Allodynia Symptom Checklist (ASC) scores, presence of allodynia, and Migraine Disability Assessment (MIDAS) scores were recorded and the 2 groups were compared statistically. Logistic regression was used to determine the independent risk factors for a conversion to CM. Results: The mean age of the 492 patients (408 female, 84 male) was 36.03±12.67 years, the disease duration was 10.78±10.36 years, the attack frequency was 10.35±9.06 attacks/month, and the attack duration was 30.10±23.54 hours. There were 115 patients (104 female, 11 male) with CM. Female gender (p=0.015), attack frequency (p

PDF

___

1. Özge A, Uluduz D, Selekler M, Öztürk M, Baykan B, Çınar N, et al. Gender differences in older adults with chronic migraine in Turkey. Geriatr Gerontol Int 2015;15(5):652–8.
2. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(10):1456–70.
3. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31(3):301–15.
4. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache 2008;48(8):1157–68.
5. Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders: 3rd edition (beta version). Cephalalgia 2013;33:629–808.
6. Becker WJ. The Diagnosis and Management of Chronic Migraine in Primary Care. Headache 2017;57(9):1471–81.
7. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 2016;12(8):455–64.
8. Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine: Evidence from high-resolution fMRI. Neurology 2017;88(21):2011–16.
9. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990;13(4):227–36.
10. Heller GZ, Manuguerra M, Chow R. How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance. Scand J Pain 2016;13:67–75.
11. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008;63(2):148–58.
12. Yalın OÖ, Uludüz D, Sungur MA, Sart H, Özge A. Identification of Allodynic Migraine Patients with the Turkish Version of the Allodynia Symptom Checklist: Reliability and Consistency Study. Noro Psikiyatr Ars 2017;54(3):260–6.
13. Ekizoglu E, Baykan B, Orhan EK, Ertas M. The analysis of allodynia in patients with idiopathic intracranial hypertension. Cephalalgia 2012;32(14):1049–58.
14. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999;19(2):107–14.
15. Ertaş M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, et al. Validity and reliability of the Turkish Migraine Disability Assessment (MIDAS) questionnaire. Headache 2004;44(8):786–93.
16. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559–66.
17. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995;24(3):612–8.
18. Özge A. Critical evaluation of headache classifications. Noro Psikiyatr Ars 2013;50(Suppl 1):8–13.
19. Aydın Özemir Z, Baykan B. The Face of Chronic Migraine Which Has Started to be Clarified. Noro Psikiyatr Ars 2013;50(Suppl1):21–5.
20. Belfer I. Pain in women. Agri 2017;29(2):51–4.
21. Yetkin Özden S, Baykan B, Ertekin E. Investigation of obsessive-compulsive symptoms in patients with migraine. Agri 2015;27(1):18–25.
22. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 2017;16(1):76–87.
23. Maleki N, Linnman C, Brawn J, Burstein R, Becerra L, Borsook D. Her versus his migraine: Multiple sex differences in brain function and structure. Brain 2012;135(Pt 8):2546–59.
24. Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache 2008;48(8):1186–93.
25. Brandes JL. Migraine in women. Continuum (Minneap Minn) 2012;18(4):835–52.
26. Güven B, Güven H, Çomoğlu S. Clinical characteristics of menstrually related and non-menstrual migraine. Acta Neurol Belg 2017;117(3):671–6.
27. Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53(8):1278–99.
28. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 2015;55(2):103–22.
29. Scher AL, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106(1-2):81–9.
30. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007;47(1):13–21.
31. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache 2008;48(1):7–15.
32. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008;70(17):1525–33.
33. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004;55(1):27–36.
34. Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache 2007;47(4):531–9.
35. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47(5):614–24.
36. Aurora SK, Brin MF. Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. Headache 2017;57(1):109–25.
37. Zeeberg P, Olesen J, Jensen R. Probable medication overuse headache: the effect of a 2-month drug-free period. Neurology 2006;66(12):1894–8. 38. Bonavita V, De Simone R. The lesson of chronic migraine. Neurol Sci 2015;36(Suppl1):101–07.
39. Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, Pini LA. Basal cutaneous pain threshold in headache patients. J Headache Pain 2011;12(3):303–10.